Search
Confirm
Close

ABOUT Viwit

With high-quality products and services, we continue to create more value for our customers, employees, shareholders and society, and contribute our talents and efforts to a healthier and better life

COMPANY PROFILE

    Viwit is an innovation driven biopharmaceutical and healthcare company with integrated research and development, production and marketing systems. Viwit is committed to building a platform for pharmaceutical innovation and commercialization, and establishing an ecosystem that serves the healthcare needs of the general public.

    Viwit was founded in 2006 as an R&D lab. With the collaborative efforts of the Viwit team, Viwit Pharmaceutical has evolved from developing chiral borane products to making drug intermediates, active pharmaceutical ingredients and biopharmaceutical products. Viwit has two integrated product research and development (R&D) centers, three cGMP production facilities (refer to history of Viwit), and marketing distribution systems in China, the United States, Canada, European Union and other regions. Viwit is continuously focusing and expanding its business scope and operations in the biopharmaceutical and healthcare industry.

威智医药

PRODUCT INTRODUCTION

We are committed to developing into a global leading medical and health enterprise based on the overall competitive advantage of the industrial chain and based on technological innovation


HIGH DEMAND PRODUCTS

Adhering to customer demand, building core competitiveness, and striving to provide better and higher quality health products and services

Title

Levofloxacin Hydrochloride Injection 5ml: 0.5g

【Drug Name】<br/> &nbsp&nbsp&nbsp&nbspGeneric Name: Levofloxacin Hydrochloride Injection<br/>
&nbsp&nbsp&nbsp&nbspEnglish Name: Levofloxacin Hydrochloride Injection<br/>
【Specification】 (1)5ml: 0.5g(Calculated as levofloxacin) (2)5ml: 0.3g(Calculated as levofloxacin)<br/>
【Indications】 In order to reduce the production of drug-resistant bacteria and ensure the effectiveness of levofloxacin hydrochloride and other antibacterial drugs, levofloxacin is only used to treat or prevent infections that have been or are highly suspected to be caused by sensitive bacteria. When selecting or modifying antimicrobial treatment regimens, the results of bacterial culture and drug susceptibility testing should be considered. If data from these trials are not available for reference, empirical treatment should be conducted based on local epidemiology and pathogen sensitivity.<br/>
Title

Levofloxacin hydrochloride Injection 5ml: 0.3g

【Drug name】 <br/>&nbsp&nbsp&nbsp&nbspEnglish Name:Levofloxacin Hydrochloride Injection<br/>
【Specification】(1)5ml: 0.5g(Calculated as levofloxacin) (2)5ml: 0.3g(Calculated as levofloxacin) <br/>
【Indications】 In order to reduce the production of drug-resistant bacteria and ensure the effectiveness of levofloxacin hydrochloride and other antibacterial drugs, levofloxacin is only used to treat or prevent infections that have been or are highly suspected to be caused by sensitive bacteria. When selecting or modifying antimicrobial treatment regimens, the results of bacterial culture and drug susceptibility testing should be considered. If data from these trials are not available for reference, empirical treatment should be conducted based on local epidemiology and pathogen sensitivity.<br/>
Title

Puerarin Injection 5ml: 0.25g

【Drug Name】 <br/>
&nbsp&nbsp&nbsp&nbspGeneric Name: Puerarin Injection<br/>
&nbsp&nbsp&nbsp&nbspEnglish Name: Puerarin Injection<br/>
【Specification】 (1)5ml: 0.25g (2)8ml: 0.4g<br/>
【Indications】 It is used to assist in the treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, and sudden deafness. <br/>
Title

Puerarin Injection 8ml: 0.4g

【Drug Name】<br/> &nbsp&nbsp&nbsp&nbspGeneric Name: Puerarin Injection<br/>
&nbsp&nbsp&nbsp&nbspEnglish Name: Puerarin Injection<br/>
【Specification】(1)5ml: 0.25g (2)8ml: 0.4g <br/>
【Indications】 It is used to assist in the treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, and sudden deafness. <br/>

INNOVATION 

& collaboration platform 

CDMO

Viwit platform provides CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, vials, eye drops). 

威智医药

Project Collaboration

Viwit platform provides R&D project cooperation and commercialization, covering the entire pharma industrial value chain from finished drugs to APIs.              

威智医药
威智医药

Joint Venture

Provide marketing, fund raising and other resources.

In-/Out-Licensing

Viwit is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets.

威智医药

NEWS CENTER

Make due contribution to the development of the industry and society, and strive to become the pacesetter and pioneer of the industry.

2022

11 -09

As the world's largest pharmaceutical industry exhibition, CPHI has been successfully held for 30 years. It displays the entire pharmaceutical supply chain, from API, P-MEC to FDF. It becomes the largest annual gathering of pharmaceutical professionals all over the world. Viwit met old friends and new business partners at CPHI. We displayed a wonderful enterprise image with our products and services, and promoted our international business through CPHI.

2019

06 -18

CPhI China 2019 will be held at Shanghai New International Expo Center on June 18-20, 2019. Welcome to patronage of Viwit, booth number: W2B28. If you would like to make an appointment in advance, please email us at service@viwit.com.

2018

12 -12

CPhI India 2018, Booth No. 4.H15 CPhI India 2018 will take place on Dec. 12 - Dec. 14, 2018 at India Expo Center, India. Please visit us on CPhI India 2018, Booth No. 4.H15. If you would like to make an appointment, please send an e-mail to service@viwit.com.

2018

12 -12

Welcome participants in CPhI India 2018, booth number: 4.H15 CPhI India 2018 will be held from December 12th to 14th, 2018 at the Expo Center in Delhi, India. Welcome to patronage of Viwit, booth number: 4.H15. If you want to make an appointment in advance, please send an email to service@viwit.com

2018

10 -11

In September 2018, Viwit's API factory in Tengzhou, Shandong Province ushered in a five-day GMP audit by Health Canada. In the end, Welcome successfully completed the GMP inspection by Health Canada and achieved excellent results. Any regulatory inspection is a challenge, but it is also a great opportunity to demonstrate your capabilities. Viwit has always adhered to the concept of cGMP standards and is committed to following high standards of quality management system. The successful on-site inspection by Health Canada is another milestone achievement by Viwit as a world-leading pharmaceutical and health company. Viwit will continue to follow the cGMP standards for each operation procedure to provide the market with safer and higher quality products.